3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasm Metastasis
3
Multiple Myeloma
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Richter's Transformation
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Liver Neoplasms
1
Glioma
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Castration Levels of Testosterone
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Renal Cell
1
Interventions
Temozolomide
28
Radiosurgery
19
Radiotherapy
17
Bevacizumab
12
Magnetic Resonance Spectroscopy
9
Radiation
6
Erlotinib Hydrochloride
6
Carboplatin
6
Topotecan
5
Nivolumab
5
Mental Status and Dementia Tests
5
Irinotecan
5
Capecitabine
5
pembrolizumab
4
dabrafenib
4
Trastuzumab
4
Sunitinib
4
Pemetrexed
4
Ipilimumab
4
Filgrastim
4
Cyclophosphamide
4
Aminolevulinic Acid
4
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
4
cabozantinib
3
Vorinostat
3
TPI-287
3
Specimen Handling
3
Radiotherapy, Intensity-Modulated
3
Methylphenidate
3
Lomustine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Brain Neoplasms
×
selinexor
×
Clear all
NCT01986348
2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2
Terminated
76 enrolled
16 charts